Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles - A recombinant vaccine candidate
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
38901737
DOI
10.1016/j.antiviral.2024.105941
PII: S0166-3542(24)00150-5
Knihovny.cz E-resources
- Keywords
- Adjuvants, Leishmania tarentolae, Tick-borne encephalitis virus, Vaccine, Virus-like particles,
- MeSH
- Adjuvants, Immunologic * administration & dosage MeSH
- Adjuvants, Vaccine administration & dosage MeSH
- Immunogenicity, Vaccine MeSH
- Injections, Intramuscular MeSH
- Interferon-gamma immunology MeSH
- Encephalitis, Tick-Borne * prevention & control immunology MeSH
- Leishmania * immunology MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Antibodies, Neutralizing blood immunology MeSH
- Antibodies, Viral * blood immunology MeSH
- Vaccines, Synthetic * immunology administration & dosage MeSH
- Th1 Cells immunology MeSH
- Viral Vaccines * immunology administration & dosage MeSH
- Encephalitis Viruses, Tick-Borne * immunology MeSH
- Vaccines, Virus-Like Particle * immunology administration & dosage MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic * MeSH
- Adjuvants, Vaccine MeSH
- Interferon-gamma MeSH
- Antibodies, Neutralizing MeSH
- Antibodies, Viral * MeSH
- Vaccines, Synthetic * MeSH
- Viral Vaccines * MeSH
- Vaccines, Virus-Like Particle * MeSH
Tick-borne encephalitis virus (TBEV) is a tick-borne flavivirus that induces severe central nervous system disorders. It has recently raised concerns due to an expanding geographical range and increasing infection rates. Existing vaccines, though effective, face low coverage rates in numerous TBEV endemic regions. Our previous work demonstrated the immunogenicity and full protection afforded by a TBEV vaccine based on virus-like particles (VLPs) produced in Leishmania tarentolae cells in immunization studies in a mouse model. In the present study, we explored the impact of adjuvants (AddaS03™, Alhydrogel®+MPLA) and administration routes (subcutaneous, intramuscular) on the immune response. Adjuvanted groups exhibited significantly enhanced antibody responses, higher avidity, and more balanced Th1/Th2 response. IFN-γ responses depended on the adjuvant type, while antibody levels were influenced by both adjuvant and administration routes. The combination of Leishmania-derived TBEV VLPs with Alhydrogel® and MPLA via intramuscular administration emerged as a highly promising prophylactic vaccine candidate, eliciting a robust, balanced immune response with substantial neutralization potential.
References provided by Crossref.org
